Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ballondor: R-VRD in Waldenström's Macroglobulinemia
NCT03697356Phase 2Recruiting
- Start
- Mar 2019
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in Waldenström's macroglobulinemia (WM). Started Mar 2019; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT03697356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697356.